Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02717507 · OUTCOME

Average Aspartate Aminotransferase

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors · Source last updated 2025-04-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
IU/L
Interval / dispersion
Standard Error
Time frame
Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

What was measured

A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors.

Analysis population: We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.

Groups in this outcome

Arm I (Carvedilol)

Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.

Arm II (Placebo)

Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Carvedilol)75
Arm II (Placebo)76

Reported measurements

BL
Values in IU/L · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Arm I (Carvedilol)26.6081.726Not reportedNot reportedNot reported
Arm II (Placebo)25.7731.089Not reportedNot reportedNot reported
6m
Values in IU/L · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Arm I (Carvedilol)24.0681.293Not reportedNot reportedNot reported
Arm II (Placebo)26.3421.252Not reportedNot reportedNot reported
12m
Values in IU/L · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Arm I (Carvedilol)25.4261.423Not reportedNot reportedNot reported
Arm II (Placebo)27.0141.432Not reportedNot reportedNot reported
18m
Values in IU/L · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Arm I (Carvedilol)24.3751.637Not reportedNot reportedNot reported
Arm II (Placebo)28.4112.665Not reportedNot reportedNot reported
24m
Values in IU/L · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Arm I (Carvedilol)24.5611.488Not reportedNot reportedNot reported
Arm II (Placebo)27.0381.509Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    -4.877
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.685
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    2.439
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.97
    param Type
    Slope
    param Value
    -0.096
    statistical Comment
    The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.
    statistical Method
    Generalized Estimating Equation (GEE)
Complete source fields
analyses
  1. ci Lower Limit
    -4.877
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    4.685
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    2.439
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.97
    param Type
    Slope
    param Value
    -0.096
    statistical Comment
    The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.
    statistical Method
    Generalized Estimating Equation (GEE)
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.726
        value
        26.608
      2. group Id
        OG001
        spread
        1.089
        value
        25.773
    title
    BL
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.293
        value
        24.068
      2. group Id
        OG001
        spread
        1.252
        value
        26.342
    title
    6m
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.423
        value
        25.426
      2. group Id
        OG001
        spread
        1.432
        value
        27.014
    title
    12m
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.637
        value
        24.375
      2. group Id
        OG001
        spread
        2.665
        value
        28.411
    title
    18m
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.488
        value
        24.561
      2. group Id
        OG001
        spread
        1.509
        value
        27.038
    title
    24m
denoms
  1. counts
    1. group Id
      OG000
      value
      75
    2. group Id
      OG001
      value
      76
    units
    Participants
description
A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors.
dispersion Type
Standard Error
groups
  1. description
    Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.
    id
    OG000
    title
    Arm I (Carvedilol)
  2. description
    Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.
    id
    OG001
    title
    Arm II (Placebo)
param Type
MEAN
population Description
We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.
reporting Status
POSTED
time Frame
Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
title
Average Aspartate Aminotransferase
type
SECONDARY
unit Of Measure
IU/L

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice